Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Влияние анемии на течение сердечно-сосудистых заболеваний

https://doi.org/10.15829/1728-8800-2016-1-64-68

Полный текст:

Аннотация

Анемия, определяемая согласно рекомендациям Всемирной организации здравоохранения, как снижение уровня гемоглобина <130 г/л у мужчин и 120 г/л у женщин, является независимым фактором риска сердечно-сосудистых заболеваний. Снижение уровня гемоглобина на 10 г/л увеличивает риск смертности от коронарной патологии. В обзоре описаны основные патофизиологические механизмы связи анемии и заболеваний сердечно-сосудистой системы, кратко приводятся результаты сравнительно недавних исследований в этой области, рассматривается их значение в клинической практике.

Об авторах

А. В. Будневский
ГБОУ ВПО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» Минздрава России. Воронеж
Россия
д.м.н., профессор, зав. кафедрой факультетской терапии


Е. С. Овсянников
ГБОУ ВПО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» Минздрава России. Воронеж
Россия
к.м.н., доцент кафедры факультетской терапии


А. В. Редька
ГБОУ ВПО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» Минздрава России. Воронеж
Россия
ординатор кафедры госпитальной терапии и эндокринологии


Список литературы

1. Lipgic E, Asselbergs FW, van der Meer P, et al. Anaemia predicts cardiovascular events in patients with stable coronary artery disease. Netherlands Heart J 2005; 13: 254-8.

2. Naito Y, Tsujino T, Matsumoto M, et al. Adaptive response of the heart to long–term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009; 296: 585-93.

3. Anderson J, Glynn LG, Newell J, et al. The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. BMC Cardiovascular Disorders 2009; 9: 51-8.

4. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. JACC 2013; 62: 147-239.

5. Upadhya B, Ntim W, Brandon Stacey R, et al. Prolongation of QTc intervals and risk of death among patients with sickle cell disease. Eur J Haematol 2013; 91: 170-8.

6. Anker SD, Voors A, Okonko D, et al. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. Eur Heart J 2009; 30: 1331-9.

7. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry. Am J Cardiol 2008; 101: 223-30.

8. Turner SJ, Ketch TR, Gandhi SK, et al. Routine hematologic clinical tests as prognosticmarkers in patients with acute coronary syndromes. Am Heart J 2008; 155: 806-16.

9. Tang YD, Katz SD. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113: 2454-61.

10. Berry C, Hogg K, Norrie J, et al. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 2005; 91: 907-13.

11. Detterich J, Noetzli L, Dorey F, et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol 2012; 87: 139-44.

12. Westenbrink BD, Voors AA, de Boer RA, et al. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Failure 2010; 12: 676-84.

13. Anand S. Anemia and chronic heart failure. JACC 2008; 52: 501-11.

14. Kazory Т, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure. JACC 2009; 53: 639-47.

15. Jankowska EA, von Haehling S, Anker SD, et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J 2013; 34: 816-29.

16. Ruifrok WPT, Qian C, Sillj´e HH, et al. Heart failure associated anemia: bone marrow dysfunction and response to erythropoietin. J Molecul Med 2011; 89: 377-87.

17. Pakbaz Z, Wun T. Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematol/Oncol Clin North Am 2014; 28: 355-74.

18. Palazzuoli А, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152: 9-15.

19. Zeng YJ, Liu GF, Liu LP, et al. Anemia on admission increases the risk of mortality at 6 months and 1 year in hemorrhagic stroke patients in China. J Stroke and Cerebrovasc Dis 2014; 23: 1500-05.

20. Singh K, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med 2006; 355: 2085-98.

21. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 2006; 355: 2071-84.

22. Jie KE, Verhaar MC, Cramer MJM, et al. Erythropoietin and the cardiorenal syndrome: cellular mechanisms on the cardiorenal connectors. Am J Physiol 2006; 291: 932-44.

23. Toblli JE, Lombrana A, Duarte P, et al. Intravenous iron reduces NT-Pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. JACC 2007; 50: 1657-65.

24. Usmanov RI, Zueva EB, Silverberg DS, et al. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J Nephrol 2008; 21: 236-42.

25. Jankowska EA, Kasztura M. Sokolski M, et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur Heart J 2014; 35: 2468-76.

26. Locatelli F, Pozzoni P, del Vecchio L, et al. Effect of anemia on left ventricular hypertrophy in end-stage renal disease. Eur J Heart Failure Supplements 2006; 2: 207-12.

27. Crary SE, Troendle S, Ahmad N, et al. Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis. Pediatric Blood and Cancer 2010; 55: 684-9.

28. Bindra K, Berry C, Rogers J, et al. Abnormal haemoglobin levels in acute coronary syndromes. QJM 2006; 99: 851-62.

29. Gonz´alez-Ferrer JJ, Garc´ıa-Rubira JC, Balcones DV, et al. Influence of hemoglobin level on in-hospital prognosis in patients with acute coronary syndrome. Revista Esp de Card 2008; 61: 945-52.

30. Kurek T, Lenarczyk R, Kowalczyk J, et al. Effect of anemia in high-risk groups of patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2010; 105: 611-8.

31. Bassand JP, Afzal R, Eikelboom J, et al. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J 2010; 31: 50-8.

32. Steinvil M, Banai S, Leshem-Rubinow E, et al. The development of anemia of inflammation during acute myocardial infarction. International J Cardiol 2012; 156: 160-4.

33. Madjid M, Fatemi O. Components of the complete blood count as risk predictors for coronary heart disease: in-depth review and update. Texas Heart Institute J 2013; 40: 17-29.

34. Archbold RA, Balami D, Hajiri AA, et al. Hemoglobin concentration is an independent determinant of heart failure in acute coronary syndromes: cohort analysis of 2310 patients. Am Heart J 2006; 152: 1091-5.

35. Osadnik T, Strzelczyk J, Hawranek M, et al. Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease. BMC Cardiovascular Disorders 2013; 13: 113-8.

36. Tonelli M, Sacks F, Arnold M, et al. Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008; 117: 163-8.

37. Ovbiagele B. Elevated red blood cell distribution width predicts mortality in persons with known stroke. J Neurolog Scien 2009; 277: 103-8.

38. Arant CB, Wessel TR, Olsonet MB, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain: results from the National Heart, Lung, and Blood Institute women’s ischemia syndrome evaluation study. JACC 2005; 43: 2009-14.

39. Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thrombosis and Haemost 2008; 6: 1289-95.

40. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005; 111: 2042-9.

41. Wilfred NC, Woodman R, DePasquale C. Prevalence and correlates of anaemia in essential hypertension. Clin Experim Pharmacol Physiol 2008; 35: 1461-4.

42. Freudenberger RS, Carson JL. Is there an optimal hemoglobin value in the cardiac intensive care unit? Curr Opin Critic Care 2005; 9: 356-61.

43. Marketou M, Patrianakos A, Parthenakis F, et al. Systemic blood pressure profile in hypertensive patients with low hemoglobin concentrations. International J Cardiol 2010; 142: 95-6.

44. Bindra K, Berry C, Rogers J, et al. Abnormal haemoglobin levels in acute coronary syndromes. QJM 2006; 851-62.

45. Diamond PT, Gale SD, Evans BA. Relationship of initial hematocrit level to discharge estination and resource utilization after ischemic stroke: a pilot study. Archiv Physical Medicine and Rehabilitation 2005; 84: 964-7.


Для цитирования:


Будневский А.В., Овсянников Е.С., Редька А.В. Влияние анемии на течение сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2016;15(1):64-68. https://doi.org/10.15829/1728-8800-2016-1-64-68

For citation:


Budnevsky A.V., Ovsyannikov E.S., Red`ka A.V. The influence of anemia on cardiovascular disease course. Cardiovascular Therapy and Prevention. 2016;15(1):64-68. (In Russ.) https://doi.org/10.15829/1728-8800-2016-1-64-68

Просмотров: 195


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)